GeneDx Holdings Corp (WGS)
19.66
+0.16
(+0.82%)
USD |
NASDAQ |
May 03, 16:00
19.76
+0.10
(+0.48%)
After-Hours: 20:00
GeneDx Holdings Cash from Operations (TTM): -141.00M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -141.00M |
December 31, 2023 | -180.15M |
September 30, 2023 | -214.94M |
June 30, 2023 | -262.08M |
March 31, 2023 | -293.22M |
Date | Value |
---|---|
December 31, 2022 | -319.16M |
September 30, 2022 | -306.49M |
June 30, 2022 | -289.06M |
March 31, 2022 | -229.72M |
December 31, 2021 | -190.43M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-319.16M
Minimum
Dec 2022
-141.00M
Maximum
Mar 2024
-242.62M
Average
-245.90M
Median
Cash from Operations (TTM) Benchmarks
American Well Corp | -148.34M |
GoodRx Holdings Inc | 138.29M |
Privia Health Group Inc | 80.78M |
Doximity Inc | 166.79M |
GE HealthCare Technologies Inc | 2.052B |